References
- Priyanka, Choudhary OP, Singh I, et al. Aerosol transmission of SARS-CoV-2: The unresolved paradox. Travel Med Infect Dis. 2020;37:101869.
- World Health O. WHO Coronavirus (COVID-19) dashboard 2022. [cited 2022 September 16]. Available from: https://covid19.who.int/.
- Bian L, Liu J, Gao F, et al. Research progress on vaccine efficacy against SARS-CoV-2 variants of concern. Hum Vaccin Immunother. 2022;18(5):2057161.
- Zuo F, Abolhassani H, Du L, et al. Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant. Nat Commun. 2022;13(1):2670.
- Ying B, Scheaffer SM, Whitener B, et al. Boosting with variant-matched or historical mRNA vaccines protects against Omicron infection in mice. Cell. 2022;185(9):1572–1587.e11.
- National Health Commission of the People’s Republic of China. COVID-19 vaccines Vaccination Status. 2022. [cited 2022 September 17]. Available from: http://www.nhc.gov.cn/xcs/yqfkdt/202209/108bb99e4bb844fa9f83b4b41a297f15.shtml.
- Pfizer. Pfizer and BioNTech initiate study to evaluate Omicron-based COVID-19 vaccine in adults 18 to 55 years of age 2022 [cited 2022 January 25]. Available from: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-initiate-study-evaluate-omicron-based.
- Sinovac. SINOVAC Omicron-specific vaccine approved for clinical trial in Hong Kong 2022 [cited 2022 April 17]. Available from: http://www.sinovac.com.cn/news/shownews.php?id=1448&lang=en.
- Link-Gelles R, Levy ME, Gaglani M, et al. Effectiveness of 2, 3, and 4 COVID-19 mRNA vaccine doses among immunocompetent adults during periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 sub-lineages predominated — VISION Network, 10 States, December 2021–June 2022. MMWR Morb Mortal Wkly Rep. 2022;71(29):931–939.
- Pajon R, Doria-Rose NA, Shen X, et al. SARS-CoV-2 Omicron variant neutralization after mRNA-1273 booster vaccination. N Engl J Med. 2022;386(11):1088–1091.
- He Q, Mao Q, An C, et al. Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates. Emerg Microbes Infect. 2021;10(1):629–637.
- Pfizer. Pfizer and BioNTech announce Omicron-adapted COVID-19 vaccine candidates demonstrate high immune response against Omicron 2022 [cited 2022 June 25]. Available from: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-omicron-adapted-covid-19.